Sprycel (dasatinib) is a prescription drug used to treat certain types of leukemia. Sprycel’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL ® (dasatinib) Support, a useful ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once ...
Sprycel (dasatinib) is a brand-name oral tablet that’s prescribed for certain types of leukemia in adults and some children. The cost of the drug, with and without insurance, can depend on several ...
The labeling for Sprycel (dasatinib; Bristol-Myers Squibb and Otsuka) has been updated with new three-year efficacy and safety data in patients with newly diagnosed Philadelphia chromosome-positive ...
The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for SPRYCEL to include a lower ...
SPRYCEL, an oral BCR-ABL inhibitor, is currently approved by the FDA for the treatment of adults for all phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or ...
Bristol-Myers Squibb Company BMY announced that the European Commission (EC) has approved its oncology drug Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients ...
NEW YORK (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers reported on ...
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results